Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of single and multiple doses of ritonavir on the pharmacokinetics of venetoclax.

Trial Profile

Effect of single and multiple doses of ritonavir on the pharmacokinetics of venetoclax.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs Ritonavir (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2018 Data from this trial was used to develop and validate a semi-mechanistic model of Ritonavir CYP3A-mediated drug-drug interaction (DDI) with Venetoclax, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 09 Jan 2018 New trial record
    • 04 Jan 2018 Results published in the European Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top